Abstract 523P
Background
The aim of this study was to investigate the impact of main co-morbidities in China: hypertension, type 2 diabetes and chronic hepatitis B viral (HBV) infection on overall survival of patients with extensive-stage small-cell lung cancer (SCLC).
Methods
Between 2009 and 2018, patients with pathologically diagnosis of SCLC in our hospital were reviewed, and the extensive stage cases were recruited in present study. Patients were divided into hypertension and non-hypertension, diabetes and non-diabetes, HBV-positive and HBV-negative group. The overall survival (OS) was evaluated using the Kaplan-Meier method and Cox proportional hazard models in each group respectively. This work was approved by the West China Hospital Research Ethics Board.
Results
Totally, 1345 SCLC patients were reviewed. 632 patients (46.9%) were confirmed with extensive-stage SCLC and analyzed. The median OS in present study was 14.6 months (95% confidence interval (CI) 13.8-15.4 months). The OS of patients with type 2 diabetes (median 17.3 months, 95% CI 14.9-19.8 months) and HBV infection (median 19.9 months, 95% CI 16.1-23.7 months) were significantly improved, comparing to the patients without diabetes (median 14.2 months, 95% CI 13.4-15.1 months) and HBV infection (median 14.2 months, 95% CI 13.4-15.0 months), respectively (p < 0.05). No significant difference in OS was observed in hypertension and non-hypertension group (median 15.7 vs. 14.4 months, p > 0.05). The prognosis significantly decreased if the patients with type 2 diabetes (HR = 0.78, 95% CI: 0.62-0.99, p = 0.046) and HBV infection (HR = 0.61, 95% CI: 0.45-0.83, p = 0.001), comparing to those patients without diabetes or HBV infection.
Conclusions
Present data indicated that the co-morbidities (type 2 diabetes and HBV infection) might be associated with the favorable prognosis in extensive-stage SCLC patients. Prospective studies are warranted to verify our findings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Department of Thoracic Oncology and State Key Laboratory of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, PR China.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
YO9 - Small Malignant Phyllodes Tumor of the Breast with Metastases to the Lung and Bone
Presenter: Gusti Harti
Session: Poster display session
Resources:
Abstract
YO10 - Rectal Follicular Dendritic Cell Sarcoma
Presenter: Kripa Bajaj
Session: Poster display session
Resources:
Abstract
YO11 - Postoperative metastasis prediction based on portal vein circulating tumor cells detected by flow cytometry in periampullary or pancreatic cancer
Presenter: Lianyuan Tao
Session: Poster display session
Resources:
Abstract
YO12 - Case report of Hepatic EBV-associated smooth muscle tumor in AIDS patient
Presenter: Gorawich Kerkarchachai
Session: Poster display session
Resources:
Abstract
YO13 - IgG4-related pseudo-tumor of the kidney and multiple organ involvement mimicked malignancy
Presenter: Wasamol Mahaparn
Session: Poster display session
Resources:
Abstract
YO14 - Urachal Adenocarcinoma: Case Report
Presenter: Michelle Joane Alcantara
Session: Poster display session
Resources:
Abstract
YO15 - Concurrent Atezolizumab-Radiotherapy in Locally Recurrent Urinary Bladder Carcinoma: A Case Report
Presenter: Ma. Angelle Lalaine Dantes
Session: Poster display session
Resources:
Abstract
YO16 - Clear cell RCC with synchronous metastasis at transplanted kidney and bone in patient post Cadaveric donor kidney transplantation
Presenter: Punyaporn Cheewasathianchai
Session: Poster display session
Resources:
Abstract
YO17 - Serous ovarian cancer treated with palbociclib and letrozole
Presenter: Dai Wee Lee
Session: Poster display session
Resources:
Abstract
YO18 - A patient with Peutz-Jegher syndrome who incidentally found sex cord stromal tumor: a case report
Presenter: Pongput Pimsa
Session: Poster display session
Resources:
Abstract